Neuroregeneration and vascular protection by Citalopram in acute ischemic stroke (TALOS) A randomized controlled study

Stroke

Volumn 49, Issue 11, 2018, Pages 2568-2576

  Kraglund, Kristian Lundsgaard ^a   Mortensen, Janne Kaergaard ^a   Damsbo, Andreas Gammelgaard ^a   Modrau, Boris ^b   Simonsen, Sofie Amalie ^c   Iversen, Helle Klingenberg ^c   Madsen, Morten ^a   Grove, Erik Lerkevang ^a,d   Johnsen, Søren Paaske ^d   Andersen, Grethe ^a,d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

citalopram; drug effects; myocardial infarction; serotonin; stroke

Indexed keywords

ALANINE AMINOTRANSFERASE; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASYMPTOMATIC DISEASE; BODY MASS; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DENMARK; DEPRESSION; DETERIORATION; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; FRACTURE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MELENA; MENTAL DISEASE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEOPLASM; NERVE REGENERATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; POST-STROKE DEPRESSION; PRIORITY JOURNAL; PULMONARY ASPIRATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RESPIRATORY TRACT DISEASE; RISK REDUCTION; SKIN MANIFESTATION; STOMACH HEMORRHAGE; STROKE SURVIVOR; STROKE UNIT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UROGENITAL TRACT DISEASE; EARLY INTERVENTION; MIDDLE AGED; NEUROPROTECTION; ODDS RATIO; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGENERATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CITALOPRAM; DENMARK; DOUBLE-BLIND METHOD; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUROPROTECTION; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGENERATION; SEROTONIN UPTAKE INHIBITORS; STROKE; YOUNG ADULT;

EID: 85055595139     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.117.020067     Document Type: Article

References (38)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359: 1317-1329. doi: 10.1056/NEJMoa0804656
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014; 129: e28-e292. doi: 10.1161/01.cir.0000441139.02102.80
3. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015; 372: 11-20. doi: 10.1056/NEJMoa1411587
4. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015; 372: 1019-1030. doi: 10.1056/NEJMoa1414905
5. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006; 59: 467-477. doi: 10.1002/ana.20741
6. Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011; 19: 1007-1015. doi: 10.1097/JGP.0b013e31821181b0
7. Guo Y, He Y, Tang B, Ma K, Cai Z, Zeng S, et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. Restor Neurol Neurosci. 2016; 34: 177-187. doi: 10.3233/RNN-150535
8. He YT, Tang BS, Cai ZL, Zeng SL, Jiang X, Guo Y. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. J Stroke Cerebrovasc Dis. 2016; 25: 761-770. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.035
9. Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, Hashemilar M, Nikanfar M, Ghazanfari Amlashi S, et al. Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial. Neurorehabil Neural Repair. 2017; 31: 638-647. doi: 10.1177/1545968317704902
10. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011; 10: 123-130. doi: 10.1016/S1474-4422(10)70314-8
11. Kim JS, Lee EJ, Chang DI, Park JH, Ahn SH, Cha JK, et al; EMOTION Investigators. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry. 2017; 4: 33-41. doi: 10.1016/S2215-0366(16)30417-5
12. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007; 18: 391-418. doi: 10.1097/FBP.0b013e3282ee2aa8
13. Wiltrout C, Lang B, Yan Y, Dempsey RJ, Vemuganti R. Repairing brain after stroke: a review on post-ischemic neurogenesis. Neurochem Int. 2007; 50: 1028-1041. doi: 10.1016/j.neuint.2007.04.011
14. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009; 87: 1037-1045. doi: 10.1002/jnr.21899
15. Tae KS, Mi SK, Ho YL, Moo SS, Si GK, Chi DK, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean J. Physiol. Pharmacol. 2009; 13: 257-263.
16. Pälvimäki EP, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J. Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology (Berl). 1994; 115: 543-546.
17. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012; 11: CD009286. doi: 10.1002/14651858.CD009286.pub2
18. Mortensen JK, Larsson H, Johnsen SP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke. 2013; 44: 420-426. doi: 10.1161/STROKEAHA.112.674242
19. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med. 2008; 168: 180-185. doi: 10.1001/archinternmed.2007.32
20. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011; 28: 345-367. doi: 10.2165/11589340-000000000-00000
21. Rasmussen A, Christensen J, Clemmensen PM, Dalsgaard NJ, Dam H, Hindberg I, et al. Platelet serotonin transporter in stroke patients. Acta Neurol Scand. 2003; 107: 150-153.
22. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010; 71: 1565-1575. doi: 10.4088/JCP.09r05786blu
23. Odaka Y, Takahashi J, Tsuburaya R, Nishimiya K, Hao K, Matsumoto Y, et al. Plasma concentration of serotonin is a novel biomarker for coronary microvascular dysfunction in patients with suspected angina and unobstructive coronary arteries. Eur Heart J. 2017; 38: 489-496. doi: 10.1093/eurheartj/ehw448
24. Kraglund KL, Mortensen JK, Grove EL, Johnsen SP, Andersen G. TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. Int J Stroke. 2015; 10: 985-987. doi: 10.1111/ijs.12485
25. Mortensen JK, Johnsen SP, Larsson H, Andersen G. Early antidepressant treatment and all-cause 30-day mortality in patients with ischemic stroke. Cerebrovasc Dis. 2015; 40: 81-90. doi: 10.1159/000435819
26. GUSTO Investigators. An international randomized Trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 1993; 329: 673-682. doi: 10.1056/NEJM199309023291001
27. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990; 1: 43-46.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18: 695-706.
29. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH stroke scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999; 53: 126-131.
30. Mortensen JK, Larsson H, Johnsen SP, Andersen G. Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality. Stroke. 2014; 45: 2121-2123. doi: 10.1161/STROKEAHA. 114.005302
31. Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol. 2014; 29: 185-196. doi: 10.1097/YIC.0000000000000023
32. Tan S, Huang X, Ding L, Hong H. Efficacy and safety of citalopram in treating post-stroke depression: a meta-analysis. Eur Neurol. 2015; 74: 188-201. doi: 10.1159/000441446
33. Mortensen JK, Andersen G. Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients. Expert Opin Drug Saf. 2015; 14: 911-919. doi: 10.1517/14740338.2015. 1033396
34. Van Holten TC, Roest M, Riphagen J, Jansen C, Naarding P, Adriaansen HJ, et al. Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study. J Thromb Haemost. 2012; 10: 1177-1179. doi: 10.1111/j.1538-7836.2012.04703.x
35. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dosedependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996; 51: 73-78.
36. Sundbøll J, Adelborg K, Munch T, Frøslev T, Sørensen HT, Bøtker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open. 2016; 6: e012832. doi: 10.1136/bmjopen-2016-012832
37. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015; 7: 449-490. doi: 10.2147/CLEP.S91125
38. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011; 42: 1489-1494. doi: 10.1161/STROKEAHA.110.602615